

Deog-Yeon Jo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6351589/publications.pdf>

Version: 2024-02-01

73
papers

776
citations

687363

13
h-index

526287

27
g-index

73
all docs

73
docs citations

73
times ranked

1159
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. <i>Journal of Clinical Investigation</i> , 2000, 105, 101-111.	8.2	226
2	Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. <i>International Journal of Hematology</i> , 2013, 97, 749-757.	1.6	98
3	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. <i>Journal of Korean Medical Science</i> , 2016, 31, 214.	2.5	51
4	Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1 α . <i>Oncology Reports</i> , 2012, 28, 2239-2246.	2.6	47
5	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57.	1.6	41
6	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 83, 309-313.	1.6	32
7	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28
8	Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature. <i>Oncology Letters</i> , 2015, 10, 3310-3314.	1.8	23
9	Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. <i>Leukemia and Lymphoma</i> , 2009, 50, 1163-1173.	1.3	20
10	Human bone marrow endothelial cells elaborate non-stromal cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors. <i>British Journal of Haematology</i> , 2003, 121, 649-652.	2.5	18
11	Overexpression of Stromal Cell-derived Factor-1 Enhances Endothelium-supported Transmigration, Maintenance, and Proliferation of Hematopoietic Progenitor Cells. <i>Stem Cells and Development</i> , 2006, 15, 260-268.	2.1	18
12	Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells. <i>Blood Research</i> , 2015, 50, 218.	1.3	17
13	Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 790-797.	1.7	15
14	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. <i>Annals of Hematology</i> , 2016, 95, 125-133.	1.8	14
15	Induction of Angiogenesis by Matrigel Coating of VEGF-Loaded PEG/PCL-Based Hydrogel Scaffolds for hBMSC Transplantation. <i>Molecules and Cells</i> , 2015, 38, 663-668.	2.6	11
16	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	1.3	11
17	Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma. <i>Cancer Research and Treatment</i> , 2015, 47, 465-472.	3.0	10
18	Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1190-1203.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Interferon β Has Dual Potential in Inhibiting or Promoting Survival and Growth of Hematopoietic Progenitors: Interactions with Stromal Cell-Derived Factor 1. International Journal of Hematology, 2006, 84, 143-150.	1.6	8
20	Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2011, 118, 3166-3166.	1.4	7
21	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Research, 2016, 51, 193.	1.3	6
22	Oncologists' Experience with Patients with Second Primary Cancer and the Attitudes toward Second Primary Cancer Screening: A Nationwide Survey. Cancer Research and Treatment, 2015, 47, 600-606.	3.0	6
23	Bortezomib inhibits the survival and proliferation of bone marrow stromal cells. Blood Research, 2015, 50, 87.	1.3	5
24	Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis. International Journal of Hematology, 2021, 114, 35-43.	1.6	5
25	Volumetric Splenomegaly in Patients With Polycythemia Vera. Journal of Korean Medical Science, 2022, 37, e87.	2.5	5
26	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. Journal of Korean Medical Science, 2014, 29, 61.	2.5	4
27	C-X-C motif receptor 7 in gastrointestinal cancer. Oncology Letters, 2015, 10, 1227-1232.	1.8	4
28	Association Between Elevated Hemolysis at Diagnosis and Early Mortality and Risk of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients with Cytopenia. Blood, 2010, 116, 4241-4241.	1.4	4
29	Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria. Blood Research, 2019, 54, 284-285.	1.3	3
30	Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies. Hematology, 2021, 26, 96-102.	1.5	3
31	Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget, 2017, 8, 79414-79424.	1.8	3
32	Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. Blood Research, 2020, 55, 77-84.	1.3	3
33	Pernicious Anemia: A Retrospective Analysis of 22 Cases. The Korean Journal of Hematology, 2005, 40, 219.	0.7	3
34	A Case of Central Nervous System Myelomatosis Developing after Allogeneic Hematopoietic Stem Cell Transplantation. The Korean Journal of Hematology, 2008, 43, 194.	0.7	2
35	A Case of Multiple Myeloma Associated with Multifocal Osteosclerosis (Multiple Myeloma with) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	2
36	Just Toxicity, or Toxicity As a Biomarker of Efficacy of Ramucirumab in Breast Cancer?. Journal of Clinical Oncology, 2015, 33, 2712-2712.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab. <i>Blood Research</i> , 2017, 52, 337.	1.3	2
38	Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. <i>Annals of Hematology</i> , 2019, 98, 2273-2281.	1.8	2
39	Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms. <i>Internal Medicine</i> , 2022, 61, 3483-3490.	0.7	2
40	CXCR4 antagonists in hematologic malignancies: more than just mobilizers?. <i>The Korean Journal of Hematology</i> , 2011, 46, 209.	0.7	1
41	Sorafenib for patients with differentiated thyroid cancer. <i>Lancet</i> , The, 2015, 385, 228.	13.7	1
42	Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging At Diagnosis in Patients with Multiple Myeloma. <i>Blood</i> , 2012, 120, 3999-3999.	1.4	1
43	The CXCR4 Antagonist AMD3100 Stimulates the Proliferation of Myeloma Cells.. <i>Blood</i> , 2008, 112, 1701-1701.	1.4	1
44	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. <i>Blood</i> , 2013, 122, 3720-3720.	1.4	1
45	Outcomes of patients with essential thrombocythemia and unnoticed thrombocytosis prior to diagnosis. <i>Blood Research</i> , 2020, 55, 281-282.	1.3	1
46	A Case of Soft Tissue Bleeding Due to a Possible Drug Interaction between Warfarin and TS-1. <i>The Korean Journal of Hematology</i> , 2005, 40, 271.	0.7	0
47	A Case of Limbic Encephalitis Developed after Allogeneic Stem Cell Transplantation. <i>The Korean Journal of Hematology</i> , 2006, 41, 297.	0.7	0
48	Fighting back against chronic myelomonocytic leukemia. <i>Blood Research</i> , 2013, 48, 165.	1.3	0
49	Two Cases of Intravascular Lymphoma Presenting with Pulmonary Involvement. <i>Journal of Korean Medical Science</i> , 2016, 31, 1011.	2.5	0
50	Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 77, 120-128.	1.4	0
51	<i>Helicobacter pylori</i> testing in a population of Korean patients with pernicious anemia. <i>Blood Research</i> , 2020, 55, 69-69.	1.3	0
52	Clinical features and outcomes of hypocellular acute myeloid leukemia in adults. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	1.0	0
53	Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3. <i>Leukemia Research</i> , 2021, 105, 106578.	0.8	0
54	Direct and Indirect Effects of Oxymetholone on Growth and Apoptosis of Hematopoietic Progenitor Cells In Vitro.. <i>Blood</i> , 2004, 104, 4127-4127.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Over-Expression of Stromal Cell-Derived Factor-1 in Non-Specialized Endothelium Enhances the Endothelium-Supported Transmigration, Maintenance, and Proliferation of Hematopoietic Progenitor Cells.. Blood, 2005, 106, 2299-2299.	1.4	0
56	Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.. Blood, 2005, 106, 3500-3500.	1.4	0
57	Dexamethasone Down-Regulates Stromal Cell-Derived Factor-1 Production in Bone Marrow Stromal Cells: Implications in Myeloma Cell Biology.. Blood, 2005, 106, 2510-2510.	1.4	0
58	Association of cis-Acting rs530 of the ETS2 Transcriptional Factor Gene with High-Risk Acute Myelogenous Leukemia (AML) and Allelic Expression Imbalance Assessment.. Blood, 2006, 108, 2230-2230.	1.4	0
59	GST T1 and GST M1 Polymorphisms Are Associated with the Risk of Acute Myeloid Leukemia. Blood, 2008, 112, 3978-3978.	1.4	0
60	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. Blood, 2009, 114, 4881-4881.	1.4	0
61	The CXCR4 Antagonist AMD3100 Has Dual Effects, Initially Enhancing and Later Inhibiting Survival and Proliferation, in Myeloid Leukemia Cells in Vitro.. Blood, 2009, 114, 1721-1721.	1.4	0
62	Prognostic Factors on Survival After Hematopoietic Stem Cell Transplantation for Adult Over 40 Years In Aplastic Anemia.. Blood, 2010, 116, 1315-1315.	1.4	0
63	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri.. Blood, 2010, 116, 1125-1125.	1.4	0
64	Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,. Blood, 2011, 118, 3424-3424.	1.4	0
65	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866.	1.4	0
66	Hepatic Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acquired Aplastic Anemia. Blood, 2011, 118, 3012-3012.	1.4	0
67	Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2011, 118, 5273-5273.	1.4	0
68	Clinical Features of Severe Acquired ADAMTS13 Deficiency in Thrombotic Thrombocytopenic Purpura: Second Report of the Korean TTP Registry.. Blood, 2012, 120, 2188-2188.	1.4	0
69	Bortezomib Inhibits the Survival and Proliferation of Bone Marrow Stromal Cells Via Downregulation of the Chemokine CXCL12. Blood, 2012, 120, 3951-3951.	1.4	0
70	Risk of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria Presenting with Both Clinical Symptoms and Elevated Hemolysis. Blood, 2012, 120, 1273-1273.	1.4	0
71	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 5151-5151.	1.4	0
72	Prognostic Implications of Abdominal Computed Tomography at Diagnosis in Patients with Polycythemia Vera or Essential Thrombocythemia. Blood, 2015, 126, 5200-5200.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry. <i>Blood</i> , 2015, 126, 4789-4789.	1.4	0